DK1165113T3 - Anvendelse af ErbB-receptorligander i behandling af diabetes - Google Patents

Anvendelse af ErbB-receptorligander i behandling af diabetes

Info

Publication number
DK1165113T3
DK1165113T3 DK00921827T DK00921827T DK1165113T3 DK 1165113 T3 DK1165113 T3 DK 1165113T3 DK 00921827 T DK00921827 T DK 00921827T DK 00921827 T DK00921827 T DK 00921827T DK 1165113 T3 DK1165113 T3 DK 1165113T3
Authority
DK
Denmark
Prior art keywords
erbb receptor
receptor ligands
diabetes
methods
treatment
Prior art date
Application number
DK00921827T
Other languages
English (en)
Inventor
Xiaojian Huang
Timothy Andrew Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1165113T3 publication Critical patent/DK1165113T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
DK00921827T 1999-04-06 2000-04-05 Anvendelse af ErbB-receptorligander i behandling af diabetes DK1165113T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12801799P 1999-04-06 1999-04-06
PCT/US2000/009240 WO2000059525A2 (en) 1999-04-06 2000-04-05 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES

Publications (1)

Publication Number Publication Date
DK1165113T3 true DK1165113T3 (da) 2008-09-08

Family

ID=22433188

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00921827T DK1165113T3 (da) 1999-04-06 2000-04-05 Anvendelse af ErbB-receptorligander i behandling af diabetes

Country Status (12)

Country Link
US (2) US20060029605A1 (da)
EP (1) EP1165113B1 (da)
JP (1) JP4794049B2 (da)
AT (1) ATE397959T1 (da)
AU (1) AU4209300A (da)
CA (1) CA2368017A1 (da)
DE (1) DE60039160D1 (da)
DK (1) DK1165113T3 (da)
ES (1) ES2307505T3 (da)
IL (2) IL145674A0 (da)
PT (1) PT1165113E (da)
WO (1) WO2000059525A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2008509093A (ja) * 2004-08-06 2008-03-27 ノヴォザイムズ グロペップ リミテッド 糖尿病治療法
WO2006128125A2 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN101410509B (zh) * 2006-02-23 2016-05-18 维亚赛特公司 用于培养可分化细胞的组合物和方法
EP2094303A1 (en) 2006-12-22 2009-09-02 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
CN101735346B (zh) * 2008-11-07 2012-05-30 中国石油天然气股份有限公司 一种丙烯均聚和共聚的催化剂及其制备方法和应用
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CA3212301A1 (en) * 2013-02-06 2014-08-14 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CA2919477A1 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
KR102027750B1 (ko) * 2018-05-03 2019-10-02 연세대학교 산학협력단 당 배출용 조성물
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
KR102109385B1 (ko) * 2019-08-21 2020-05-12 연세대학교 산학협력단 당 배출용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
JPH09511384A (ja) * 1994-01-24 1997-11-18 リサーチ トライアングル ファーマシューティカルズ リミテッド 若年型糖尿病の治療
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
JP3945846B2 (ja) * 1995-11-09 2007-07-18 武田薬品工業株式会社 膵臓機能改善剤
AU7506396A (en) * 1995-11-09 1997-05-29 Takeda Chemical Industries Ltd. Composition for improving pancreatic function
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
ES2307505T3 (es) 2008-12-01
EP1165113B1 (en) 2008-06-11
JP4794049B2 (ja) 2011-10-12
PT1165113E (pt) 2008-09-23
DE60039160D1 (de) 2008-07-24
US20080031880A1 (en) 2008-02-07
ATE397959T1 (de) 2008-07-15
IL145674A0 (en) 2002-06-30
AU4209300A (en) 2000-10-23
CA2368017A1 (en) 2000-10-12
WO2000059525A2 (en) 2000-10-12
EP1165113A2 (en) 2002-01-02
JP2002541117A (ja) 2002-12-03
WO2000059525A3 (en) 2001-02-08
IL145674A (en) 2010-12-30
US20060029605A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
DK1165113T3 (da) Anvendelse af ErbB-receptorligander i behandling af diabetes
FI964033A (fi) Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
SG131943A1 (en) Specific binding agents to hepatocyte growth factor
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
SG160373A1 (en) Adult pancreatic derived stromal cells
BR0012196A (pt) Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
ATE403680T1 (de) Herstellung tetravalenter antikörper
DK0868505T3 (da) Chondrogen in vitro induktion af humane mesenchymstamceller
DE60234278D1 (de) Mitotische kinesin-hemmer
GT200100016A (es) Pirido[2,3,-d]pirimidin-2,7-diaminas inhibidoras de cinasas.
DE60122337D1 (de) Verwendung von taci als antitumormittel
DK0804479T3 (da) Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF
ATE317266T1 (de) In vitro methode zur synchronisation von oozytenreifung
MXPA03007261A (es) Moduladores del receptor de glucocorticoides.
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
GB0411052D0 (en) Method of producing human beta cell lines
ATE297217T1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
ATE414141T1 (de) Verfahren zur kultivierung humaner chondrozyten
MXPA01008657A (es) Aumento de la proporcion de implante por esterol que activa la meiosis.
DE60132466D1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
BR9807980A (pt) Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva